Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethinylestradiol + drospirenone + Selmevit appears to refer to a combination of two pharmaceutical agents—ethinylestradiol (a synthetic estrogen) and drospirenone (a synthetic progestin with antiandrogenic and antimineralocorticoid properties)—with "Selmevit," which is a multivitamin/mineral dietary supplement. Ethinylestradiol and drospirenone are commonly used together as an oral contraceptive for the prevention of pregnancy, as well as for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea in women[5][3][7]. Their mechanism involves suppression of ovulation via inhibition of gonadotropins, alteration of cervical mucus, and endometrial changes unfavorable to implantation[5][3]. Drospirenone also acts as an antimineralocorticoid and antiandrogen[5]. "Selmevit" is not a pharmaceutical drug but rather a multivitamin/mineral supplement; it does not have direct pharmacological action relevant to contraception or hormonal therapy. The combination described here is not recognized as a standard or approved fixed-dose product in major regulatory databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethinylestradiol + drospirenone + Selmevit.